Aclaris Therapeutics, Inc. (ACRS) earnings
ACRS earnings moved a median of +0.91% by the close. Quarterly and annual ACRS reports and results, each read against the price at its own news timestamp. Back to the ACRS overview →
22 measured ACRS earnings events.
Where these ACRS earnings landedvs 22 measured ACRS earnings reactions
| Middle 50% of ACRS earnings reactions | -2.48% to +2.28% |
|---|---|
| Median reaction (to close) | +0.91% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 ACRS earnings events with a measured close landed between -2.48% and +2.28%; 55% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update | Press release | +0.24% | -3.94% | |
| Form 10-Q Aclaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.33% | -2.80% | |
| Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update | Press release | -1.07% | +4.29% | |
| Form 10-Q Aclaris Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.32% | +2.07% | |
| Form 10-K Aclaris Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.42% | -6.82% | |
| Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -3.06% | -0.87% | |
| Form 10-Q Aclaris Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.19% | +2.65% | |
| Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.65% | +1.29% | |
| Form 10-Q Aclaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.27% | +3.82% | |
| Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.56% | +2.34% | |
| Form 10-Q Aclaris Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +3.25% | +0.00% | |
| Form 10-K Aclaris Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.74% | +4.74% | |
| Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Press release | +4.02% | +0.89% | |
| Form 10-Q Aclaris Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.76% | +7.93% | |
| Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update | Press release | +0.00% | -7.03% | |
| Form 10-Q Aclaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.67% | -2.50% | |
| Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update | Press release | -1.60% | -2.40% | |
| Form 10-Q Aclaris Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.60% | -2.40% | |
| Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update | Press release | +3.36% | +1.68% | |
| Form 10-K Aclaris Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +6.45% | -3.23% | |
| Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update | Press release | +2.21% | +0.92% | |
| Form 10-Q Aclaris Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +2.21% | +0.92% |
Keep exploring
More ACRS: analyst actions → · SEC filings → · ACRS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | 276 | +0.21% | 51% |
| Xenon Pharmaceuticals Inc. - Common Shares (XENE) | 276 | +0.03% | 50% |
| Anika Therapeutics Inc. (ANIK) | 275 | +0.07% | 52% |
| Delcath Systems, Inc. (DCTH) | 275 | -0.27% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.